A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Capital Medical University · Chinese Academy of Sciences · +12 more institutions
Abstract
Neutralizing antibodies could potentially be used as antivirals against the coronavirus disease 2019 (COVID-19) pandemic. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. The antibodies B38 and H4 block binding between the spike glycoprotein receptor binding domain (RBD) of the virus and the cellular receptor angiotensin-converting enzyme 2 (ACE2). A competition assay indicated different epitopes on the RBD for these two antibodies, making them a potentially promising virus-targeting monoclonal antibody pair for avoiding immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model…
Citation impact
- FWCI
- 26.07
- Percentile
- 100%
- References
- 21
Authors
25- YWYan WuCorresponding
Capital Medical University, Chinese Academy of Sciences, Institutes of Science and Development
- FWFeiran WangCorresponding
University of Science and Technology of China, Chinese Academy of Sciences, Institute of Microbiology
- CSChenguang ShenCorresponding
Chinese Academy of Sciences, Institute of Microbiology, Shenzhen Third People’s Hospital
- WPWeiyu PengCorresponding
Chinese Academy of Sciences, Institute of Microbiology, China Agricultural University
- DLDelin LiCorresponding
Chinese Academy of Sciences, Institute of Microbiology, Tianjin Institute of Industrial Biotechnology, Shenzhen Third People’s Hospital
Topics & keywords
- Antibody
- Virology
- Virus
- Binding site
- Coronavirus disease 2019 (COVID-19)
- Neutralizing antibody
- Biology
- Receptor
- Good health and well-being